Articles & Video
Containing Coronavirus Through Innovation and Investment: An Xconomy Special Report
This report contains ideas, innovation, and experience from some of the major players at the forefront of efforts in combatting COVID-19. The exclusive articles were captured from the BIO-Europe Spring® event and are accompanied by some of the most pertinent stories from B2B publications Xconomy and Bioprocess Insider.
A Backstage View Of Roche’s Recent Collaborations
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
Oncology Needs Combo Therapies & More Data Analysis, Says BIO-Europe Spring Panel
Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough drugs. That’s the message life sciences experts shared this week during a webcast on the topic of “oncology’s next decade” recorded for the BIO-Europe Spring partnering conference.
MedTech Report 2020: EU MDR and IVDR Compliance
Download the MedTech Report 2020 on EU MDR and IVDR Compliance, based on 265 survey responses from industry insiders.
Life Sciences in 2030 Survey: Complete to win a 2-day conference pass
We are a conducting a huge survey of life sciences professionals around the world on how the industry will look by 2030. Complete it here to get early access to the final report.
New approaches to drug discovery and development enabled by platform success
Relatively small Enabling Technology Platform companies are changing the future for patients, drug discovery scientists, therapeutic scientists, developers, new therapy approach scientists, plus payers. Sometimes, it is important to remind oneself that biotech is working for the good of the worldwide healthcare industry and not just our local markets.
Paris Region to lead the field in personalized medicine and biopharma 3.0
Medicen Paris Region is thrilled to host the 2020 edition of BIO-Europe Spring following the great success of the 2015 conference here. The Paris Region is a worldwide hub when it comes to healthcare innovation, and the very first European region when it comes to biopharma specifically. It is indeed home to 1,000+ life sciences startups, more than 1,200 public and private R&D labs and 12,000 life sciences researchers, and Europe’s largest hospital network.
MedTech 2020 Survey: EU MDR and IVDR Compliance
Complete our MedTech survey on EU MDR and IVDR Compliance to be in with a chance of winning a 2 day conference pass to MedTech Summit.
PharmAI – Industry is Smartening Up to Potential of Artificial Intelligence
Artificial Intelligence (AI) has enormous potential in changing the delivery of health care and improving patient outcomes, with applications in pattern detection, patient monitoring, disease diagnosis and treatment selection. The rationale is that AI can be used to enhance the decision-making process, taking into account far more data than are available to physicians via conventional means.
Tracking the Power of Presenting at Biotech Showcase
For the first time, Informa Pharma Intelligence explores the achievements by Biotech Showcase presenting companies, delving into the deal-making activity that has occurred for companies who have presented at the conference in the last five years.
The Power of Presenting at Biotech Showcase
Informa Pharma Intelligence analysts took a deep dive into what has happened to companies who have presented at Biotech Showcase. Since 2015, over 250 companies that have presented at Biotech Showcase have generated deals worth over $61bn.
Giving a Pharma Giant a Tech Startup Makeover
This shows how we’re using data and digital to reimagining medicine. If successful, this could open up the entire area of digital therapeutics.
Biotech VC Down 20% in US as Policies Drive Away Foreign Investors, BIO Says
Reforms to a US national security regulation are putting off foreign investors and driving down VC investment in the biotech space by as much as 20 percent, says BIO’s David Thomas.
The state of manufacturing and commercialization of microbiome therapeutics - Data report analysis
We analyse the data from our recent survey on manufacturing and commercialization in the microbiome therapeutics industry.
Digital Health: Advancing innovation through technology and strategic partnerships
Insights from investors, biopharma leaders and digital health executives on how to navigate the digital health sector as it transforms every aspect of the pharmaceutical value chain.
Pharma embraces biopartnering at BIO-Europe to address its innovation deficit
Big pharma’s appetite for early preclinical assets continues to grow and now represents the development phase with the most deals and largest total deal value. Consequently, an increasing number of academic institutions are taking the opportunity to showcase their efforts in the academic track at BIO-Europe.
BIO-Europe® 2019: Life sciences companies follow the footsteps of Hamburg’s ancient merchants as they gather to celebrate innovation and partnership
BIO-Europe, now celebrating 25 years of facilitating partnerships that drive life science dealmaking, is the perfect stage for budding biotech and pharmaceutical companies to meet and engage with delegates from all parts of the life sciences value chain.
7 predictions for how microbiome therapeutics will look in 5 years
We asked 7 industry experts for their predictions for how the microbiome therapeutics industry will look in 5 years.
The therapeutic potential of the human oral microbiome
Human Microbiome Therapeutics: Oral microbiome - Discover the therapeutic potential, current research areas and companies and where the potential growth is.